The White House said it plans to impose up to 200% tariffs on generic drugs sold in the US if companies do not manufacture in America, escalating pressure on supply chains. The pledge follows a broader push to increase domestic production capacity for pharmaceuticals. While the details of how the tariffs would apply were not fully specified in the reporting, the announcement directly targets the economics of generic drug manufacturing and sourcing. For companies with outsourced manufacturing footprints, the policy raises risks around pricing, contracts, and continuity of supply. In parallel, related policy activity continued in Congress, including bipartisan efforts that could affect aspects of drug development and reimbursement. The tariff announcement is the latest sign that trade policy is increasingly intersecting with the operational realities of drug supply in the generic market.